

Case 4-31162A/31163

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATIONS

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and

I believe I am an original, first and joint inventor of the subject matter which is claimed
and for which a patent is sought on the invention entitled

PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND
ANOTHER ANTIDIABETIC AGENT

the specification of which was filed as PCT International Application No. **PCT/EP00/09816** on
October 6, 2000 and entered the national stage in the United States and was accorded
Application No.

I hereby state that I have reviewed and understand the contents of the above identified
specification, including the claims, as amended by any amendments made during the
international stage (including any made under PCT Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose all information which is known by me to be material to
the patentability of this application as defined in 37 C.F.R. §1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign
application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any
PCT international application(s) designating at least one country other than the United States
listed below and have also listed below any foreign application(s) for patent or inventor's
certificate or any PCT international application(s) designating at least one country other than the
United States for the same subject matter and having a filing date before that of the application
the priority of which is claimed for that subject matter:

None

I hereby claim the benefit under 35 USC §119(e) of any United States provisional
application(s) listed below:

Application No.Filing Date

60/287,564

October 8, 1999

60/287,584

October 8, 1999

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any PCT international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose all information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>United States Application No.</u>	<u>United States Filing or §371 Date</u>	<u>Status or U.S. Patent No.</u>	<u>International Application No.</u>	<u>International Filing Date</u>
--	--	--------------------------------------	--	--------------------------------------

I hereby appoint the attorneys and agents associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

I hereby authorize my aforementioned attorneys and agents and any others acting on my behalf to take any action relating to this application based on communications from the Patents and Trademarks Division of Novartis Services AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please address all communications to the address associated with ~~Customer No.~~ 001095, which is currently Thomas Hoxie, Novartis Corporation, Patent and Trademark Dept., 564 Morris Avenue, Summit, NJ 07901-1027.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FIRST JOINT INVENTOR:

170

Full name : **Marj ri Regan Gatlin**

Signature :

Marj ri Regan Gatlin

Date :

07/23/02
(MM/DD/YY)

Citizenship : United States of America

Residence : Chicago, Illinois 60618P.O. Address : 3632 North Seeley Avenue
Chicago Illinois 60618

CS

SECOND JOINT INVENTOR:

JEW

Full name : **Michele Ball**

Signature :

Michele Ball

Date :

07/11/02
(MM/DD/YY)

Citizenship : United States of America

Residence : Kendall Park, New JerseyP.O. Address : 9 Shady Lane
Kendall Park, New Jersey 08824

NJ

THIRD JOINT INVENTOR:

Full name : **Beth Dunning**

Signature :

Date :

(MM/DD/YY)

Citizenship : United States of America

Residence : Battle Creek, Michigan

P.O. Address : 272 Orchard Avenue
Battle Creek, Michigan 49017

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATIONS

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,
and °

I believe I am an original, first and joint inventor of the subject matter which is claimed
and for which a patent is sought on the invention entitled

PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND
ANOTHER ANTIDIABETIC AGENT

the specification of which was filed as PCT International Application No. **PCT/EP00/09816** on
October 6, 2000 and entered the national stage in the United States and was accorded
Application No.

I hereby state that I have reviewed and understand the contents of the above identified
specification, including the claims, as amended by any amendments made during the
international stage (including any made under PCT Rule 91, Article 19 and Article 34).

I acknowledge my duty to disclose all information which is known by me to be material to
the patentability of this application as defined in 37 C.F.R. §1.56.

I hereby claim the benefit under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign
application(s) for patent or inventor's certificate listed below and under 35 U.S.C. §365(a) of any
PCT international application(s) designating at least one country other than the United States
listed below and have also listed below any foreign application(s) for patent or inventor's
certificate or any PCT international application(s) designating at least one country other than the
United States for the same subject matter and having a filing date before that of the application
the priority of which is claimed for that subject matter:

None

I hereby claim the benefit under 35 USC §119(e) of any United States provisional
application(s) listed below:

Application No.Filing Date

60/287,564

October 8, 1999

60/287,584

October 8, 1999

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) listed below and under 35 U.S.C. §365(c) of any PCT international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose all information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date(s) of the prior application(s) and the national or PCT international filing date of this application:

<u>United States Application No.</u>	<u>United States Filing or §371 Date</u>	<u>Status or U.S. Patent No.</u>	<u>International Application No.</u>	<u>International Filing Date</u>
--	--	--------------------------------------	--	--------------------------------------

I hereby appoint the attorneys and agents associated with Customer No. 001095, respectively and individually, as my attorneys and agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

I hereby authorize my aforementioned attorneys and agents and any others acting on my behalf to take any action relating to this application based on communications from the Patents and Trademarks Division of Novartis Services AG, Basle, Switzerland, or an affiliate thereof or a successor thereto, without direct communication from me.

Please address all communications to the address associated with Customer No. 001095, which is currently Thomas Hoxie, Novartis Corporation, Patent and Trademark Dept., 564 Morris Avenue, Summit, NJ 07901-1027.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FIRST JOINT INVENTOR:

Full name : **Marjorie Regan Gatlin**

Signature : _____

Date : _____
(MM/DD/YY)

Citizenship : United States of America

Residence : Chicago, Illinois 60618

P.O. Address : 3632 North Seeley Avenue
Chicago Illinois 60618

SECOND JOINT INVENTOR:

Full name : **Michele Ball**

Signature : _____

Date : _____
(MM/DD/YY)

Citizenship : United States of America

Residence : Kendall Park, New Jersey

P.O. Address : 9 Shady Lane
Kendall Park, New Jersey 08824

THIRD JOINT INVENTOR:

Full name : **Beth Dunning**Signature : *Beth Dunning*Date : *7/16/02*
(MM/DD/YY)

Citizenship : United States of America

Residence : Battle Creek, Michigan

P.O. Address : 272 Orchard Avenue
Battle Creek, Michigan 49017 *MT*

IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.